JP2015520169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520169A5 JP2015520169A5 JP2015514099A JP2015514099A JP2015520169A5 JP 2015520169 A5 JP2015520169 A5 JP 2015520169A5 JP 2015514099 A JP2015514099 A JP 2015514099A JP 2015514099 A JP2015514099 A JP 2015514099A JP 2015520169 A5 JP2015520169 A5 JP 2015520169A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding entity
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102000013691 Interleukin-17 Human genes 0.000 claims 9
- 108050003558 Interleukin-17 Proteins 0.000 claims 9
- 102000013264 Interleukin-23 Human genes 0.000 claims 7
- 108010065637 Interleukin-23 Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims 3
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims 3
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims 3
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 3
- 206010053869 POEMS syndrome Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019375 Helicobacter infections Diseases 0.000 claims 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 206010023335 Keratitis interstitial Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000024526 cutaneous mucinosis Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000006904 interstitial keratitis Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000010241 mucinoses Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650286P | 2012-05-22 | 2012-05-22 | |
| US61/650,286 | 2012-05-22 | ||
| US201361784600P | 2013-03-14 | 2013-03-14 | |
| US61/784,600 | 2013-03-14 | ||
| US201361787890P | 2013-03-15 | 2013-03-15 | |
| US61/787,890 | 2013-03-15 | ||
| PCT/US2013/041928 WO2013177101A2 (en) | 2012-05-22 | 2013-05-21 | Bispecific antibodies and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520169A JP2015520169A (ja) | 2015-07-16 |
| JP2015520169A5 true JP2015520169A5 (enExample) | 2016-07-14 |
| JP6362587B2 JP6362587B2 (ja) | 2018-07-25 |
Family
ID=48539425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514099A Expired - Fee Related JP6362587B2 (ja) | 2012-05-22 | 2013-05-21 | Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9708401B2 (enExample) |
| EP (2) | EP3456741B1 (enExample) |
| JP (1) | JP6362587B2 (enExample) |
| CN (1) | CN104884473B (enExample) |
| AR (1) | AR091116A1 (enExample) |
| ES (2) | ES2711554T3 (enExample) |
| LT (1) | LT2852615T (enExample) |
| SI (1) | SI2852615T1 (enExample) |
| TW (1) | TWI609882B (enExample) |
| UY (1) | UY34815A (enExample) |
| WO (1) | WO2013177101A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| JP2009534297A (ja) | 2006-03-10 | 2009-09-24 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法 |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| TW201622743A (zh) * | 2014-03-19 | 2016-07-01 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 免疫原醣肽、包含該醣肽之組合物及其用途 |
| EP4050026A1 (en) | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
| CR20160519A (es) * | 2014-05-13 | 2017-01-27 | The Trustees Of The Univ Of Pennysylvania | Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| JP6779200B2 (ja) * | 2014-07-24 | 2020-11-04 | アカデミア シニカ | 川崎病の診断及び治療 |
| CA3081058C (en) * | 2015-01-16 | 2024-02-20 | Academia Sinica | Linker units and their uses in configuring pharmaceutical molecules |
| EP3250927B1 (en) * | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| EP3304079B1 (en) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| CA2986066A1 (en) * | 2015-06-30 | 2017-01-05 | Boehringer Ingelheim International Gmbh | Multi-specific binding proteins |
| PE20180774A1 (es) * | 2015-07-23 | 2018-05-07 | Boehringer Ingelheim Int | Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos |
| CA2994865A1 (en) | 2015-09-09 | 2017-03-16 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| MX2018006072A (es) | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| TN2019000082A1 (en) * | 2016-09-14 | 2020-07-15 | Beijing hanmi pharm co ltd | Antibody specifically binding to il-17a and functional fragment thereof |
| KR102321861B1 (ko) | 2017-03-10 | 2021-11-05 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도 |
| CN110475565A (zh) * | 2017-03-16 | 2019-11-19 | 光明之火生物科学公司 | 软骨归巢肽缀合物及其使用方法 |
| WO2018213297A1 (en) | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
| CN107384960B (zh) * | 2017-07-25 | 2020-06-12 | 吉优诺（上海）基因科技有限公司 | 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用 |
| CN107854490A (zh) * | 2017-09-26 | 2018-03-30 | 首都医科大学附属北京世纪坛医院 | 一种经修饰的t细胞及其应用 |
| AU2018361975A1 (en) | 2017-11-02 | 2020-05-07 | Novartis Ag | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists |
| KR102048475B1 (ko) * | 2017-11-10 | 2019-11-26 | 주식회사 와이바이오로직스 | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 |
| CN110305210B (zh) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN108929903B (zh) * | 2018-04-23 | 2021-07-16 | 东莞市第五人民医院(东莞市太平人民医院) | 用于慢性牙周炎筛查、诊断、疗效评价的标志物及试剂盒 |
| US12098195B2 (en) | 2018-11-27 | 2024-09-24 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-IL-23p19 antibody and use thereof in treating diseases |
| GB201820556D0 (en) | 2018-12-17 | 2019-01-30 | Alligator Bioscience Ab | Novel polypeptides |
| CN113603783B (zh) | 2018-12-21 | 2022-07-12 | 浙江时迈药业有限公司 | 蛋白酶可切割的双特异性抗体及其用途 |
| CN110330566A (zh) * | 2019-06-11 | 2019-10-15 | 南京华岩生物技术有限公司 | 一种具有双重可变结构域的双特异性结合的免疫球蛋白 |
| BR112022021780A2 (pt) * | 2020-04-27 | 2023-03-07 | Twist Bioscience Corp | Bibliotecas de ácido nucléico variantes para coronavírus |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021238932A1 (zh) * | 2020-05-26 | 2021-12-02 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| CN111718414B (zh) | 2020-06-12 | 2021-03-02 | 江苏荃信生物医药有限公司 | 抗人白介素23单克隆抗体及其应用 |
| CN111944046B (zh) * | 2020-08-28 | 2021-04-09 | 江苏荃信生物医药有限公司 | 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法 |
| JP2025516772A (ja) | 2022-05-16 | 2025-05-30 | ノバルティス アーゲー | インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いて巨細胞性動脈炎を治療する方法 |
| AU2023270497A1 (en) | 2022-05-18 | 2024-12-05 | Novartis Ag | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |
| WO2025245150A1 (en) * | 2024-05-20 | 2025-11-27 | The Trustees Of Columbia University In The City Of New York | Anti-pd-1 x il-25 bispecific antibody to treat cancer |
| WO2026072963A1 (en) * | 2024-09-27 | 2026-04-02 | Shattuck Labs, Inc. | Bispecific antibodies that bind tnfrsf25 and il-23/il-23r |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US6291189B1 (en) | 1994-05-10 | 2001-09-18 | Carta Proteomics, Inc. | Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites |
| US5658739A (en) | 1994-05-10 | 1997-08-19 | The Regents Of The University Of California | Method for characterization of the fine structure of protein binding sites |
| US6902735B1 (en) | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| ATE474849T1 (de) | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
| BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
| US20030199041A1 (en) | 1999-07-07 | 2003-10-23 | Presnell Scott R. | Interleukin-17 receptor homologue |
| PT2857516T (pt) * | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| DK1641822T3 (da) | 2003-07-08 | 2013-07-22 | Genentech Inc | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. |
| UA97086C2 (uk) * | 2003-07-15 | 2012-01-10 | Емджен, Інк. | Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf) |
| US8716023B2 (en) | 2003-12-09 | 2014-05-06 | Novozymes, Inc. | Methods for eliminating or reducing the expression of a genes in a filamentous fungal strains |
| AU2005241020B2 (en) | 2004-05-03 | 2008-07-10 | Merck Sharp & Dohme Corp. | Use of IL-17 expression to predict skin inflammation; methods of treatment |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| EP1765865A2 (en) | 2004-06-10 | 2007-03-28 | ZymoGenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CN101218254A (zh) | 2005-02-14 | 2008-07-09 | 惠氏公司 | 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途 |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| SI1937721T1 (sl) | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| DE602006009834D1 (de) | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| PL1963368T6 (pl) * | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| CA2637166A1 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies for treating cancer |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| JP2009534297A (ja) | 2006-03-10 | 2009-09-24 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法 |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| TWI390034B (zh) | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| NZ574804A (en) | 2006-08-11 | 2012-02-24 | Schering Corp | Antibodies to il-17a |
| ES2465223T3 (es) * | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
| AU2007352412B2 (en) | 2007-04-27 | 2013-05-16 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| EP2535350B1 (en) * | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| EP2281845B1 (en) | 2008-04-25 | 2020-09-02 | Kyowa Kirin Co., Ltd. | Stable polyvalent antibody |
| BRPI0908312A2 (pt) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
| EP2297209A4 (en) * | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| NZ594514A (en) | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| JP5972871B2 (ja) * | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
-
2013
- 2013-05-21 AR ARP130101765 patent/AR091116A1/es unknown
- 2013-05-21 WO PCT/US2013/041928 patent/WO2013177101A2/en not_active Ceased
- 2013-05-21 TW TW102117991A patent/TWI609882B/zh not_active IP Right Cessation
- 2013-05-21 US US14/402,322 patent/US9708401B2/en active Active
- 2013-05-21 LT LTEP13726375.2T patent/LT2852615T/lt unknown
- 2013-05-21 SI SI201331310T patent/SI2852615T1/sl unknown
- 2013-05-21 ES ES13726375T patent/ES2711554T3/es active Active
- 2013-05-21 ES ES18202356T patent/ES2846623T3/es active Active
- 2013-05-21 JP JP2015514099A patent/JP6362587B2/ja not_active Expired - Fee Related
- 2013-05-21 UY UY0001034815A patent/UY34815A/es unknown
- 2013-05-21 EP EP18202356.4A patent/EP3456741B1/en not_active Not-in-force
- 2013-05-21 CN CN201380038828.XA patent/CN104884473B/zh not_active Expired - Fee Related
- 2013-05-21 EP EP13726375.2A patent/EP2852615B1/en active Active
- 2013-05-21 US US13/898,544 patent/US8945553B2/en active Active
-
2014
- 2014-12-19 US US14/576,278 patent/US9783606B2/en active Active
-
2016
- 2016-10-10 US US15/289,463 patent/US20170022272A1/en not_active Abandoned
-
2017
- 2017-06-12 US US15/620,358 patent/US10358489B2/en active Active
- 2017-09-01 US US15/694,374 patent/US10358490B2/en active Active
-
2019
- 2019-06-10 US US16/435,960 patent/US11254740B2/en active Active
-
2022
- 2022-01-07 US US17/570,954 patent/US20220185877A1/en not_active Abandoned